These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

29 related articles for article (PubMed ID: 10155604)

  • 1. Alglucerase: the debate continues.
    Push S
    Pharmacoeconomics; 1995 Mar; 7(3):268-9. PubMed ID: 10155316
    [No Abstract]   [Full Text] [Related]  

  • 2. [Cost reduction in the treatment of Gaucher s disease].
    García Salom P; Acedo A
    Farm Hosp; 2007; 31(3):194-5. PubMed ID: 17941761
    [No Abstract]   [Full Text] [Related]  

  • 3. Managing public payment for high-cost, high-benefit treatment: enzyme replacement therapy for Gaucher's disease in Ontario.
    Clarke JT; Amato D; Deber RB
    CMAJ; 2001 Sep; 165(5):595-6. PubMed ID: 11563212
    [No Abstract]   [Full Text] [Related]  

  • 4. [Financing of enzyme treatment in Gaucher disease].
    Wisløff F
    Tidsskr Nor Laegeforen; 2003 Feb; 123(3):364. PubMed ID: 12640908
    [No Abstract]   [Full Text] [Related]  

  • 5. The cost of treating Gaucher disease.
    Beutler E
    Nat Med; 1996 May; 2(5):523-4. PubMed ID: 8616707
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-effectiveness controversy.
    Cox TM
    Pharmacoeconomics; 1995 Jul; 8(1):82-3. PubMed ID: 10155604
    [No Abstract]   [Full Text] [Related]  

  • 7. Alglucerase. A pharmacoeconomic appraisal of its use in the treatment of Gaucher's disease.
    Whittington R; Goa KL
    Pharmacoeconomics; 1995 Jan; 7(1):63-90. PubMed ID: 10155294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lysosomal storage diseases: natural history and ethical and economic aspects.
    Beutler E
    Mol Genet Metab; 2006 Jul; 88(3):208-15. PubMed ID: 16515872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Gaucher's disease and enzyme replacement therapy].
    Cornu F
    Ann Pharm Fr; 1998; 56(3):102-7. PubMed ID: 9770016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations.
    Charrow J; Andersson HC; Kaplan P; Kolodny EH; Mistry P; Pastores G; Prakash-Cheng A; Rosenbloom BE; Scott CR; Wappner RS; Weinreb NJ
    J Pediatr; 2004 Jan; 144(1):112-20. PubMed ID: 14722528
    [No Abstract]   [Full Text] [Related]  

  • 11. [The treatment of Gaucher's disease in The Netherlands using enzyme substitution therapy].
    Hollak CE; van Oers MH; Maaswinkel P; Aerts JM; Goudsmit R
    Ned Tijdschr Geneeskd; 1996 May; 140(19):1011-3. PubMed ID: 8684492
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.